CL2015001608A1 - Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. - Google Patents

Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.

Info

Publication number
CL2015001608A1
CL2015001608A1 CL2015001608A CL2015001608A CL2015001608A1 CL 2015001608 A1 CL2015001608 A1 CL 2015001608A1 CL 2015001608 A CL2015001608 A CL 2015001608A CL 2015001608 A CL2015001608 A CL 2015001608A CL 2015001608 A1 CL2015001608 A1 CL 2015001608A1
Authority
CL
Chile
Prior art keywords
formulation
humanized anti
proliferative disorder
antibody solution
treat autoimmune
Prior art date
Application number
CL2015001608A
Other languages
English (en)
Inventor
Ramesh S Kashi
Aniket Badkar
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2015001608A1 publication Critical patent/CL2015001608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2015001608A 2012-12-13 2015-06-10 Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. CL2015001608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
CL2015001608A1 true CL2015001608A1 (es) 2015-10-30

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001608A CL2015001608A1 (es) 2012-12-13 2015-06-10 Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.

Country Status (31)

Country Link
US (3) US20150329632A1 (es)
EP (1) EP2931313B1 (es)
JP (1) JP6266012B2 (es)
KR (1) KR102004585B1 (es)
CN (1) CN104870016B (es)
AU (1) AU2013359767B2 (es)
BR (1) BR112015013540B1 (es)
CA (1) CA2894869C (es)
CL (1) CL2015001608A1 (es)
CY (1) CY1121895T1 (es)
DK (1) DK2931313T3 (es)
EA (1) EA034616B1 (es)
ES (1) ES2732861T3 (es)
HK (1) HK1215194A1 (es)
HR (1) HRP20191137T1 (es)
HU (1) HUE045668T2 (es)
IL (3) IL307581A (es)
LT (1) LT2931313T (es)
MX (1) MX357936B (es)
MY (1) MY187921A (es)
NZ (1) NZ708443A (es)
PE (1) PE20151524A1 (es)
PH (1) PH12015501296A1 (es)
PL (1) PL2931313T3 (es)
PT (1) PT2931313T (es)
RS (1) RS59057B1 (es)
SI (1) SI2931313T1 (es)
TR (1) TR201909584T4 (es)
UA (1) UA117466C2 (es)
WO (1) WO2014093203A1 (es)
ZA (1) ZA201504408B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
KR20190129061A (ko) * 2017-03-31 2019-11-19 메이지 세이카 파루마 가부시키가이샤 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
KR20200129125A (ko) * 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
JP2022532965A (ja) * 2018-11-21 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度タンパク質製剤
WO2020172002A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
AU2020226619A1 (en) * 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
WO2021126435A1 (en) * 2019-12-20 2021-06-24 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
BR112022022919A2 (pt) * 2020-05-13 2022-12-20 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
PT3417875T (pt) 2003-02-10 2020-08-24 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
PL1601694T3 (pl) 2003-03-10 2010-02-26 Merck Sharp & Dohme Zastosowania antagonistów IL-23; pokrewne reagenty
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
ATE533502T1 (de) 2004-02-17 2011-12-15 Schering Corp Verfahren zur modulation der il-23-aktivität; relevante reagenzien
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
US7872102B2 (en) 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US20090060906A1 (en) 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009079A (es) * 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
MY171841A (en) 2007-12-21 2019-11-04 Hoffmann La Roche Antibody formulation
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
JP5642683B2 (ja) * 2008-09-19 2014-12-17 ファイザー・インク 安定な液体抗体配合物
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
LT2691112T (lt) 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
EP2822591B1 (en) * 2012-03-07 2018-05-02 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies

Also Published As

Publication number Publication date
PL2931313T3 (pl) 2019-10-31
EA201591133A1 (ru) 2015-10-30
IL278295A (es) 2020-12-31
JP2016505572A (ja) 2016-02-25
CY1121895T1 (el) 2020-10-14
DK2931313T3 (da) 2019-07-15
WO2014093203A1 (en) 2014-06-19
EA034616B1 (ru) 2020-02-27
IL278295B1 (en) 2023-11-01
KR102004585B1 (ko) 2019-07-26
PH12015501296B1 (en) 2015-08-24
PH12015501296A1 (en) 2015-08-24
RS59057B1 (sr) 2019-08-30
EP2931313A1 (en) 2015-10-21
BR112015013540B1 (pt) 2021-04-27
ZA201504408B (en) 2017-09-27
CA2894869A1 (en) 2014-06-19
MX2015007213A (es) 2016-08-03
IL239150A0 (en) 2015-07-30
IL278295B2 (en) 2024-03-01
IL307581A (en) 2023-12-01
IL239150B (en) 2020-11-30
TR201909584T4 (tr) 2019-07-22
US20210188964A1 (en) 2021-06-24
SI2931313T1 (sl) 2019-09-30
AU2013359767B2 (en) 2018-04-05
AU2013359767A1 (en) 2015-07-23
MX357936B (es) 2018-07-31
EP2931313B1 (en) 2019-05-08
PE20151524A1 (es) 2015-11-06
JP6266012B2 (ja) 2018-01-24
EP2931313A4 (en) 2016-08-03
CN104870016B (zh) 2018-05-08
UA117466C2 (uk) 2018-08-10
US20240239884A1 (en) 2024-07-18
HK1215194A1 (zh) 2016-08-19
BR112015013540A8 (pt) 2018-04-17
CA2894869C (en) 2021-06-15
HRP20191137T1 (hr) 2019-09-20
CN104870016A (zh) 2015-08-26
ES2732861T3 (es) 2019-11-26
BR112015013540A2 (pt) 2017-11-14
LT2931313T (lt) 2019-09-25
HUE045668T2 (hu) 2020-01-28
MY187921A (en) 2021-10-28
KR20150092763A (ko) 2015-08-13
NZ708443A (en) 2018-05-25
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
CL2015001608A1 (es) Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
BR112014032193A2 (pt) métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
CL2016001556A1 (es) Anticuerpos anti-cd3 y métodos de uso
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
CL2015002829A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
BR112014028366A2 (pt) anticorpos anti-ly6e e imunoconjugados e métodos de uso
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112013013781A2 (pt) anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
BR112015003938A2 (pt) métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112015007120A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
BR112014005746A2 (pt) tecidos engendrados para usos em pesquisa in vitro, arranjos destes, e métodos de fabricar os mesmos
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23